FDA's Latest: More Paperwork to Track Your Sandwich Ingredients
Published Date: 2/20/2026
Notice
Summary
The FDA just dropped a draft guide to help food makers, packers, and holders understand new rules about keeping extra records for certain foods. If you’re in the food biz, these rules mean more tracking paperwork to keep food safe and traceable. You’ve got until May 21, 2026, to send in your thoughts before the guide goes final—so get ready to update your record-keeping game!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Faster removal of unsafe food reduces illnesses
You should see fewer foodborne illnesses and deaths because the rule lets FDA identify and remove potentially contaminated food faster. The Food Traceability Rule enables faster identification and rapid removal of unsafe foods from the market.
Food businesses must keep extra records
If you manufacture, process, pack, or hold foods on the Food Traceability List (FTL), you must maintain records containing key data elements tied to specific critical tracking events and keep a written traceability plan. The rule applies to both domestic and foreign firms producing food for U.S. consumption and covers recordkeeping across the entire food supply chain.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-03362 — Requirements for Additional Traceability Records for Certain Foods; Exemption for Cottage Cheese Regulated by the National Conference on Interstate Milk Shipments Grade “A” Pasteurized Milk Ordinance
Starting February 20, 2026, certain cottage cheese made under the Grade “A” Pasteurized Milk rules won’t have to follow extra food tracking record rules. This change helps cottage cheese makers by easing paperwork without risking safety. If you make, process, or sell these cottage cheeses, this means less hassle and no new costs.
Next: 2026-03365 — State of Wyoming: NRC Staff Assessment of a Proposed Amendment to the Agreement Between the Nuclear Regulatory Commission and the State of Wyoming
The Nuclear Regulatory Commission (NRC) is proposing changes to its agreement with Wyoming about how the state handles certain nuclear materials. Wyoming’s program and staff are being reviewed to make sure they keep people safe. The public can share their thoughts by March 2, 2026, before any final decisions are made.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in